1887

Abstract

, a major periodontopathogen, has been shown to be resistant to many antibiotics. In the present study, we examined the effect of the FDA-approved iron chelators deferoxamine (DFO) and deferasirox (DFRA) against planktonic and biofilm cells of in order to evaluate the possibility of using these iron chelators as alternative control agents against . DFRA showed strong antimicrobial activity (MIC and MBC values of 0.16 mg ml) against planktonic . At subMICs, DFRA partially inhibited the bacterial growth and considerably prolonged the bacterial doubling time. DFO was unable to completely inhibit the bacterial growth in the concentration range tested and was not bactericidal. Crystal violet binding assay for the assessment of biofilm formation by showed that DFRA significantly decreased the biofilm-forming activity as well as the biofilm formation, while DFO was less effective. DFRA was chosen for further study. In the ATP-bioluminescent assay, which reflects viable cell counts, subMICs of DFRA significantly decreased the bioactivity of biofilms in a concentration-dependent manner. Under the scanning electron microscope, cells in DFRA-treated biofilm were significantly elongated compared to those in untreated biofilm. Further experiments are necessary to show that iron chelators may be used as a therapeutic agent for periodontal disease.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.053553-0
2013-09-01
2021-08-05
Loading full text...

Full text loading...

/deliver/fulltext/jmm/62/9/1307.html?itemId=/content/journal/jmm/10.1099/jmm.0.053553-0&mimeType=html&fmt=ahah

References

  1. Albandar J. M., Brown L. J., Löe H. 1997; Putative periodontal pathogens in subgingival plaque of young adults with and without early-onset periodontitis. J Periodontol 68:973–981 [View Article][PubMed]
    [Google Scholar]
  2. Andrés M. T., Chung W. O., Roberts M. C., Fierro J. F. 1998; Antimicrobial susceptibilities of Porphyromonas gingivalis, Prevotella intermedia, and Prevotella nigrescens spp. isolated in Spain. Antimicrob Agents Chemother 42:3022–3023[PubMed]
    [Google Scholar]
  3. Ardila C. M., Granada M. I., Guzmán I. C. 2010; Antibiotic resistance of subgingival species in chronic periodontitis patients. J Periodontal Res 45:557–563[PubMed]
    [Google Scholar]
  4. Ashimoto A., Chen C., Bakker I., Slots J. 1996; Polymerase chain reaction detection of 8 putative periodontal pathogens in subgingival plaque of gingivitis and advanced periodontitis lesions. Oral Microbiol Immunol 11:266–273 [View Article][PubMed]
    [Google Scholar]
  5. Bentur Y., McGuigan M., Koren G. 1991; Deferoxamine (desferrioxamine). New toxicities for an old drug. Drug Saf 6:37–46 [View Article][PubMed]
    [Google Scholar]
  6. Brook I., Frazier E. H. 2003; Immune response to Fusobacterium nucleatum and Prevotella intermedia in the sputum of patients with acute exacerbation of chronic bronchitis. Chest 124:832–833 [View Article][PubMed]
    [Google Scholar]
  7. Cable H., Lloyd J. B. 1999; Cellular uptake and release of two contrasting iron chelators. J Pharm Pharmacol 51:131–134 [View Article][PubMed]
    [Google Scholar]
  8. Cappellini M. D. 2007; ExjadeR (deferasirox, ICL670) in the treatment of chronic iron overload associated with blood transfusion. Ther Clin Risk Manag 3:291–299 [View Article][PubMed]
    [Google Scholar]
  9. Chan G. C., Chan S., Ho P. L., Ha S. Y. 2009; Effects of chelators (deferoxamine, deferiprone and deferasirox) on the growth of Klebsiella pneumoniae and Aeromonas hydrophila isolated from transfusion-dependent thalassemia patients. Hemoglobin 33:352–360 [View Article][PubMed]
    [Google Scholar]
  10. Chong A., Wehrly T. D., Nair V., Fischer E. R., Barker J. R., Klose K. E., Celli J. 2008; The early phagosomal stage of Francisella tularensis determines optimal phagosomal escape and Francisella pathogenicity island protein expression. Infect Immun 76:5488–5499 [View Article][PubMed]
    [Google Scholar]
  11. Clark W. B., Magnusson I., Beem J. E., Jung J. M., Marks R. G., McArthur W. P. 1991; Immune modulation of Prevotella intermedia colonization in squirrel monkeys. Infect Immun 59:1927–1931[PubMed]
    [Google Scholar]
  12. CLSI 2007; Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria; Approved Standard, 7th edn. Document M11-A7. Wayne, PA: Clinical and Laboratory Standards Institute;
    [Google Scholar]
  13. Denny T. P., Makini F. W., Brumbley S. M. 1988; Characterization of Pseudomonas solanacearum Tn5 mutants deficient in extracellular polysaccharide. Mol Plant Microbe Interact 1:215–223 [View Article]
    [Google Scholar]
  14. Dong L., Tong Z., Linghu D., Lin Y., Tao R., Liu J., Tian Y., Ni L. 2012; Effects of sub-minimum inhibitory concentrations of antimicrobial agents on Streptococcus mutans biofilm formation. Int J Antimicrob Agents 39:390–395 [View Article][PubMed]
    [Google Scholar]
  15. Donlan R. M. 2002; Biofilms: microbial life on surfaces. Emerg Infect Dis 8:881–890 [View Article][PubMed]
    [Google Scholar]
  16. Donlan R. M., Costerton J. W. 2002; Biofilms: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev 15:167–193 [View Article][PubMed]
    [Google Scholar]
  17. Eckert R., He J., Yarbrough D. K., Qi F., Anderson M. H., Shi W. 2006; Targeted killing of Streptococcus mutans by a pheromone-guided “smart” antimicrobial peptide. Antimicrob Agents Chemother 50:3651–3657 [View Article][PubMed]
    [Google Scholar]
  18. Escartin Q., Lallam-Laroye C., Baroukh B., Morvan F. O., Caruelle J. P., Godeau G., Barritault D., Saffar J. L. 2003; A new approach to treat tissue destruction in periodontitis with chemically modified dextran polymers. FASEB J 17:644–651 [View Article][PubMed]
    [Google Scholar]
  19. Fiehn N. E., Larsen T., Christiansen N., Holmstrup P., Schroeder T. V. 2005; Identification of periodontal pathogens in atherosclerotic vessels. J Periodontol 76:731–736 [View Article][PubMed]
    [Google Scholar]
  20. Fosse T., Madinier I., Hannoun L., Giraud-Morin C., Hitzig C., Charbit Y., Ourang S. 2002; High prevalence of cfxA β-lactamase in aminopenicillin-resistant Prevotella strains isolated from periodontal pockets. Oral Microbiol Immunol 17:85–88 [View Article][PubMed]
    [Google Scholar]
  21. Frank K. L., Reichert E. J., Piper K. E., Patel R. 2007; In vitro effects of antimicrobial agents on planktonic and biofilm forms of Staphylococcus lugdunensis clinical isolates. Antimicrob Agents Chemother 51:888–895 [View Article][PubMed]
    [Google Scholar]
  22. Fux C. A., Stoodley P., Hall-Stoodley L., Costerton J. W. 2003; Bacterial biofilms: a diagnostic and therapeutic challenge. Expert Rev Anti Infect Ther 1:667–683 [View Article][PubMed]
    [Google Scholar]
  23. Gibbons R. J., MacDonald J. B. 1960; Hemin and vitamin K compounds as required factors for the cultivation of certain strains of Bacteroides melaninogenicus. . J Bacteriol 80:164–170[PubMed]
    [Google Scholar]
  24. Glickstein H., El R. B., Shvartsman M., Cabantchik Z. I. 2005; Intracellular labile iron pools as direct targets of iron chelators: a fluorescence study of chelator action in living cells. Blood 106:3242–3250 [View Article][PubMed]
    [Google Scholar]
  25. Halliday J. W., Bassett M. L. 1980; Treatment of iron storage disorders. Drugs 20:207–215 [View Article][PubMed]
    [Google Scholar]
  26. Hanson L. R., Roeytenberg A., Martinez P. M., Coppes V. G., Sweet D. C., Rao R. J., Marti D. L., Hoekman J. D., Matthews R. B. other authors 2009; Intranasal deferoxamine provides increased brain exposure and significant protection in rat ischemic stroke. J Pharmacol Exp Ther 330:679–686 [View Article][PubMed]
    [Google Scholar]
  27. Hassan A., Usman J., Kaleem F., Omair M., Khalid A., Iqbal M. 2011; Evaluation of different detection methods of biofilm formation in the clinical isolates. Braz J Infect Dis 15:305–311[PubMed] [CrossRef]
    [Google Scholar]
  28. Heinz U., Hegetschweiler K., Acklin P., Faller B., Lattmann R., Schnebli H. P. 1999; 4-[3,5-Bis(2-hydroxyphenyl)-1,2,4-triazol-1-yl]-benzoic acid: a novel efficient and selective iron(III) complexing agent. Angew Chem Int Ed Engl 38:2568–2570 [View Article][PubMed]
    [Google Scholar]
  29. Hershko C., Konijn A. M., Nick H. P., Breuer W., Cabantchik Z. I., Link G. 2001; ICL670A: a new synthetic oral chelator: evaluation in hypertransfused rats with selective radioiron probes of hepatocellular and reticuloendothelial iron stores and in iron-loaded rat heart cells in culture. Blood 97:1115–1122 [View Article][PubMed]
    [Google Scholar]
  30. Hershko C., Link G., Konijn A. M., Cabantchik Z. I. 2005; Objectives and mechanism of iron chelation therapy. Ann N Y Acad Sci 1054:124–135 [View Article][PubMed]
    [Google Scholar]
  31. Honma K., Mishima E., Inagaki S., Sharma A. 2009; The OxyR homologue in Tannerella forsythia regulates expression of oxidative stress responses and biofilm formation. Microbiology 155:1912–1922 [View Article][PubMed]
    [Google Scholar]
  32. Kamma J. J., Nakou M., Gmür R., Baehni P. C. 2004; Microbiological profile of early onset/aggressive periodontitis patients. Oral Microbiol Immunol 19:314–321 [View Article][PubMed]
    [Google Scholar]
  33. Kontoghiorghes G. J., Kolnagou A., Skiada A., Petrikkos G. 2010; The role of iron and chelators on infections in iron overload and non iron loaded conditions: prospects for the design of new antimicrobial therapies. Hemoglobin 34:227–239 [View Article][PubMed]
    [Google Scholar]
  34. Kuru B., Yilmaz S., Noyan U., Acar O., Kadir T. 1999; Microbiological features and crevicular fluid aspartate aminotransferase enzyme activity in early onset periodontitis patients. J Clin Periodontol 26:19–25 [View Article][PubMed]
    [Google Scholar]
  35. Lauzon K., Zhao X., Lacasse P. 2006; Deferoxamine reduces tissue damage during endotoxin-induced mastitis in dairy cows. J Dairy Sci 89:3846–3857 [View Article][PubMed]
    [Google Scholar]
  36. Lesic B., Foulon J., Carniel E. 2002; Comparison of the effects of deferiprone versus deferoxamine on growth and virulence of Yersinia enterocolitica. . Antimicrob Agents Chemother 46:1741–1745 [View Article][PubMed]
    [Google Scholar]
  37. Leung K. P., Subramaniam P. S., Okamoto M., Fukushima H., Lai C. H. 1998; The binding and utilization of hemoglobin by Prevotella intermedia. . FEMS Microbiol Lett 162:227–233 [View Article][PubMed]
    [Google Scholar]
  38. Lewis J. P. 2010; Metal uptake in host-pathogen interactions: role of iron in Porphyromonas gingivalis interactions with host organisms. Periodontol 2000 52:94–116 [View Article][PubMed]
    [Google Scholar]
  39. Lewis J. P., Dawson J. A., Hannis J. C., Muddiman D., Macrina F. L. 1999; Hemoglobinase activity of the lysine gingipain protease (Kgp) of Porphyromonas gingivalis W83. J Bacteriol 181:4905–4913[PubMed]
    [Google Scholar]
  40. Liu Z. D., Hider R. C. 2002; Design of iron chelators with therapeutic application. Coord Chem Rev 232:151–171 [View Article]
    [Google Scholar]
  41. Mah T. F., O’Toole G. A. 2001; Mechanisms of biofilm resistance to antimicrobial agents. Trends Microbiol 9:34–39 [View Article][PubMed]
    [Google Scholar]
  42. McKenney D., Willcock L., Trueman P. A., Allison D. G. 1994; Effect of sub-MIC antibiotics on the cell surface and extracellular virulence determinants of Pseudomonas cepacia. . J Appl Bacteriol 76:190–195 [View Article][PubMed]
    [Google Scholar]
  43. Moon J. H., Herr Y., Kim S. W., Lee J. Y. 2011a; In vitro activity of deferoxamine against Porphyromonas gingivalis. . FEMS Microbiol Lett 323:61–67 [View Article][PubMed]
    [Google Scholar]
  44. Moon J. H., Park J. H., Lee J. Y. 2011b; Antibacterial action of polyphosphate on Porphyromonas gingivalis. . Antimicrob Agents Chemother 55:806–812 [View Article][PubMed]
    [Google Scholar]
  45. Moreau-Marquis S., O’Toole G. A., Stanton B. A. 2009; Tobramycin and FDA-approved iron chelators eliminate Pseudomonas aeruginosa biofilms on cystic fibrosis cells. Am J Respir Cell Mol Biol 41:305–313 [View Article][PubMed]
    [Google Scholar]
  46. Nakao R., Senpuku H., Watanabe H. 2006; Porphyromonas gingivalis galE is involved in lipopolysaccharide O-antigen synthesis and biofilm formation. Infect Immun 74:6145–6153 [View Article][PubMed]
    [Google Scholar]
  47. NCCLS 1999 Methods for Determining Bactericidal Activity of Antimicrobial Agents. Approved Guideline. Document M26-A Wayne, PA: National Committee for Clinical Laboratory Standards;
    [Google Scholar]
  48. Nick H., Wong A., Acklin P., Faller B., Jin Y., Lattmann R., Sergejew T., Hauffe S., Thomas H., Schnebli H. P. 2002; ICL670A: preclinical profile. Adv Exp Med Biol 509:185–203 [View Article][PubMed]
    [Google Scholar]
  49. Novak M. J. 1999; Necrotizing ulcerative periodontitis. Ann Periodontol 4:74–78 [View Article][PubMed]
    [Google Scholar]
  50. Olson M. E., Ceri H., Morck D. W., Buret A. G., Read R. R. 2002; Biofilm bacteria: formation and comparative susceptibility to antibiotics. Can J Vet Res 66:86–92[PubMed]
    [Google Scholar]
  51. Palmer R. J., Darveau R., Lamont R. J., Nyvad B., Teles R. P. 2011; Human oral bacterial biofilms: composition, dynamics, and pathogenesis. In Biofilm Infections pp. 35–68 Edited by Bjarnsholt T., Jensen P. Ø., Moser C., Høiby N. New York: Springer; [View Article]
    [Google Scholar]
  52. Petit M. D., van Steenbergen T. J., Timmerman M. F., de Graaff J., van der Velden U. 1994; Prevalence of periodontitis and suspected periodontal pathogens in families of adult periodontitis patients. J Clin Periodontol 21:76–85 [View Article][PubMed]
    [Google Scholar]
  53. Pine L., Boone C. J. 1967; Comparative cell wall analyses of morphological forms within the genus Actinomyces. . J Bacteriol 94:875–883[PubMed]
    [Google Scholar]
  54. Polson A. M., Garrett S., Stoller N. H., Bandt C. L., Hanes P. J., Killoy W. J., Southard G. L., Duke S. P., Bogle G. C. other authors 1997; Multi-center comparative evaluation of subgingivally delivered sanguinarine and doxycycline in the treatment of periodontitis. II. Clinical results. J Periodontol 68:119–126 [View Article][PubMed]
    [Google Scholar]
  55. Qu Y., Daley A. J., Istivan T. S., Rouch D. A., Deighton M. A. 2010; Densely adherent growth mode, rather than extracellular polymer substance matrix build-up ability, contributes to high resistance of Staphylococcus epidermidis biofilms to antibiotics. J Antimicrob Chemother 65:1405–1411 [View Article][PubMed]
    [Google Scholar]
  56. Rao R. S., Karthika R. U., Singh S. P., Shashikala P., Kanungo R., Jayachandran S., Prashanth K. 2008; Correlation between biofilm production and multiple drug resistance in imipenem resistant clinical isolates of Acinetobacter baumannii. . Indian J Med Microbiol 26:333–337 [View Article][PubMed]
    [Google Scholar]
  57. Rice L. B. 2006; Antimicrobial resistance in gram-positive bacteria. Am J Med 119:Suppl 1S11–S19, discussion S62–S70 [View Article][PubMed]
    [Google Scholar]
  58. Richardson D. R., Ponka P. 1998; Development of iron chelators to treat iron overload disease and their use as experimental tools to probe intracellular iron metabolism. Am J Hematol 58:299–305 [View Article][PubMed]
    [Google Scholar]
  59. Richardson D., Ponka P., Baker E. 1994; The effect of the iron(III) chelator, desferrioxamine, on iron and transferrin uptake by the human malignant melanoma cell. Cancer Res 54:685–689[PubMed]
    [Google Scholar]
  60. Rowland R. W., Mestecky J., Gunsolley J. C., Cogen R. B. 1993; Serum IgG and IgM levels to bacterial antigens in necrotizing ulcerative gingivitis. J Periodontol 64:195–201 [View Article][PubMed]
    [Google Scholar]
  61. Shibata Y., Hiratsuka K., Hayakawa M., Shiroza T., Takiguchi H., Nagatsuka Y., Abiko Y. 2003; A 35-kDa co-aggregation factor is a hemin binding protein in Porphyromonas gingivalis. . Biochem Biophys Res Commun 300:351–356 [View Article][PubMed]
    [Google Scholar]
  62. Shinzato T., Saito A. 1994; A mechanism of pathogenicity of “Streptococcus milleri group” in pulmonary infection: synergy with an anaerobe. J Med Microbiol 40:118–123 [View Article][PubMed]
    [Google Scholar]
  63. Smalley J. W., Silver J., Marsh P. J., Birss A. J. 1998a; The periodontopathogen Porphyromonas gingivalis binds iron protoporphyrin IX in the μ-oxo dimeric form: an oxidative buffer and possible pathogenic mechanism. Biochem J 331:681–685[PubMed]
    [Google Scholar]
  64. Smalley J. W., Birss A. J., McKee A. S., Marsh P. D. 1998b; Hemin regulation of hemoglobin binding by Porphyromonas gingivalis. . Curr Microbiol 36:102–106 [View Article][PubMed]
    [Google Scholar]
  65. Smalley J. W., Silver J., Birss A. J., Withnall R., Titler P. J. 2003; The haem pigment of the oral anaerobes Prevotella nigrescens and Prevotella intermedia is composed of iron(III) protoporphyrin IX in the monomeric form. Microbiology 149:1711–1718 [View Article][PubMed]
    [Google Scholar]
  66. Smith A. W. 2005; Biofilms and antibiotic therapy: is there a role for combating bacterial resistance by the use of novel drug delivery systems?. Adv Drug Deliv Rev 57:1539–1550 [View Article][PubMed]
    [Google Scholar]
  67. Soukos N. S., Som S., Abernethy A. D., Ruggiero K., Dunham J., Lee C., Doukas A. G., Goodson J. M. 2005; Phototargeting oral black-pigmented bacteria. Antimicrob Agents Chemother 49:1391–1396 [View Article][PubMed]
    [Google Scholar]
  68. Sritharan M. 2006; Iron and bacterial virulence. Indian J Med Microbiol 24:163–164[PubMed]
    [Google Scholar]
  69. Stewart P. S., Costerton J. W. 2001; Antibiotic resistance of bacteria in biofilms. Lancet 358:135–138 [View Article][PubMed]
    [Google Scholar]
  70. Takahashi N., Ishihara K., Kimizuka R., Okuda K., Kato T. 2006; The effects of tetracycline, minocycline, doxycycline and ofloxacin on Prevotella intermedia biofilm. Oral Microbiol Immunol 21:366–371 [View Article][PubMed]
    [Google Scholar]
  71. Tenover F. C. 2006; Mechanisms of antimicrobial resistance in bacteria. Am J Med 119:Suppl 1S3–S10, discussion S62–S70 [View Article][PubMed]
    [Google Scholar]
  72. Tompkins G. R., Wood D. P., Birchmeier K. R. 1997; Detection and comparison of specific hemin binding by Porphyromonas gingivalis and Prevotella intermedia. . J Bacteriol 179:620–626[PubMed]
    [Google Scholar]
  73. van Asbeck B. S., Marcelis J. H., Marx J. J. M., Struyvenberg A., van Kats J. H., Verhoef J. 1983; Inhibition of bacterial multiplication by the iron chelator deferoxamine: potentiating effect of ascorbic acid. Eur J Clin Microbiol 2:426–431 [View Article][PubMed]
    [Google Scholar]
  74. van Asbeck B. S., Marx J. J., Struyvenberg A., van Kats J. H., Verhoef J. 1984; Deferoxamine enhances phagocytic function of human polymorphonuclear leukocytes. Blood 63:714–720[PubMed]
    [Google Scholar]
  75. Vulcano M., Meiss R. P., Isturiz M. A. 2000; Deferoxamine reduces tissue injury and lethality in LPS-treated mice. Int J Immunopharmacol 22:635–644 [View Article][PubMed]
    [Google Scholar]
  76. Webb M. 1953; Effects of magnesium on cellular division in bacteria. Science 118:607–611 [View Article][PubMed]
    [Google Scholar]
  77. Weinberg K. 1990; Novel uses of deferoxamine. Am J Pediatr Hematol Oncol 12:9–13 [View Article][PubMed]
    [Google Scholar]
  78. Weiss H. M., Fresneau M., Camenisch G. P., Kretz O., Gross G. 2006; In vitro blood distribution and plasma protein binding of the iron chelator deferasirox (ICL670) and its iron complex Fe-[ICL670]2 for rat, marmoset, rabbit, mouse, dog, and human. Drug Metab Dispos 34:971–975[PubMed]
    [Google Scholar]
  79. Wills A. P., Chan E. C. 1978; Morphogenetic expression of Arthrobacter globiformis 425 in continuous culture with carbon or biotin limitation. Can J Microbiol 24:28–30 [View Article][PubMed]
    [Google Scholar]
  80. Yamanaka T., Furukawa T., Matsumoto-Mashimo C., Yamane K., Sugimori C., Nambu T., Mori N., Nishikawa H., Walker C. B. other authors 2009; Gene expression profile and pathogenicity of biofilm-forming Prevotella intermedia strain 17. BMC Microbiol 9:11 [View Article][PubMed]
    [Google Scholar]
  81. Yamanaka T., Yamane K., Furukawa T., Matsumoto-Mashimo C., Sugimori C., Nambu T., Obata N., Walker C. B., Leung K. P., Fukushima H. 2011; Comparison of the virulence of exopolysaccharide-producing Prevotella intermedia to exopolysaccharide non-producing periodontopathic organisms. BMC Infect Dis 11:228 [View Article][PubMed]
    [Google Scholar]
  82. Young K. D. 2006; The selective value of bacterial shape. Microbiol Mol Biol Rev 70:660–703 [View Article][PubMed]
    [Google Scholar]
  83. Yu F., Anaya C., Lewis J. P. 2007; Outer membrane proteome of Prevotella intermedia 17: identification of thioredoxin and iron-repressible hemin uptake loci. Proteomics 7:403–412 [View Article][PubMed]
    [Google Scholar]
  84. Zhang L., Mah T. F. 2008; Involvement of a novel efflux system in biofilm-specific resistance to antibiotics. J Bacteriol 190:4447–4452 [View Article][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.053553-0
Loading
/content/journal/jmm/10.1099/jmm.0.053553-0
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error